From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Age mean (range), years | 68.5 (32.5–91.5) |
Gender | |
Male n (%) | 39 (72%) |
Female n (%) | 15 (28%) |
Primary nodular melanoma | |
Yes n (%) | 11 (20%) |
No n (%) | 41 (76%) |
Undetermined n (%) | 2 (4%) |
Breslow thickness mean (range), mm | 4.11 (0.37–28) |
BRAF V600 status | |
Wild type n (%) | 33 (61%) |
Mutant n (%) | 13 (24%) |
Undetermined n (%) | 8 (15%) |
Previous ipilimumab n (%) | 22 (41%) |
Previous nivolumab n (%) | 0 (0%) |
Baseline tumor size before pembrolizumab mean (range), mm | 79 (5–247) |
Follow-up period median (range), months | 9 (2–35) |